Effect and mechanisms of dexmedetomidine combined with macrophage migration inhibitory factor inhibition on the expression of inflammatory factors and AMPK in mice
Clinical and Experimental Immunology · 2023
DOI: 10.1093/cei/uxad016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Siyu Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republ…. Hauptthemen laut MEDLINE: Macrophage Migration-Inhibitory Factors, Dexmedetomidine, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Reperfusion after acute myocardial infarction can cause ischemia/reperfusion (I/R) injury, which not only impedes restoration of the functions of tissues and organs but may also aggravate structural tissue and organ damage and dysfunction, worsening the patient’s condition. Thus, the mechanisms that underpin myocardial I/R injury need to be better understood. We aimed to examine the effect of dexmedetomidine on macrophage migration inhibitory factor (MIF) in cardiomyocytes from mice with myocardial I/R injury and to explore the mechanistic role of adenosine 5ʹ-monophosphate-activated protein kinase (AMPK) signaling in this process. Myocardial I/R injury was induced in mice. The expression of serum inflammatory factors, reactive oxygen species (ROS), adenosine triphosphate (ATP), and AMPK pathway-related proteins, as well as myocardial tissue structure and cell apoptosis rate, were compared between mice with I/R injury only; mice with I/R injury treated with dexmedetomidine, ISO-1 (MIF inhibitor), or both; and sham-operated mice. Dexmedetomidine reduced serum interleukin (IL)-6 and tumor necrosis factor-α concentrations and increased IL-10 concentration in mice with I/R injury. Moreover, dexmedetomidine reduced myocardial tissue ROS content and apoptosis rate and increased ATP content and MIF expression. MIF inhibition using ISO-1 reversed the protective effect of dexmedetomidine on myocardial I/R injury and reduced AMPK phosphorylation. Dexmedetomidine reduces the inflammatory response in mice with I/R injury and improves adverse symptoms, and its mechanism of action may be related to the MIF-AMPK pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, People's Republic of China.
ORCID-Profile: Jiang Wang
Förderung
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
Zitieren
APA
Chen, S., Wu, J., Li, A., Huang, Y., Tailaiti, T., Zou, T., Jiang, J., & Wang, J. (2023). Effect and mechanisms of dexmedetomidine combined with macrophage migration inhibitory factor inhibition on the expression of inflammatory factors and AMPK in mice. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad016
Vancouver
Chen S, Wu J, Li A, Huang Y, Tailaiti T, Zou T, et al. Effect and mechanisms of dexmedetomidine combined with macrophage migration inhibitory factor inhibition on the expression of inflammatory factors and AMPK in mice. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad016
BibTeX
@article{Chen2023,
author = {Chen, Siyu and Wu, Jianjiang and Li, Aimei and Huang, Yidan and Tailaiti, Taiwangu and Zou, Tiantian and Jiang, Jin and Wang, Jiang},
title = {Effect and mechanisms of dexmedetomidine combined with macrophage migration inhibitory factor inhibition on the expression of inflammatory factors and AMPK in mice},
journal = {Clinical and Experimental Immunology},
year = {2023},
doi = {10.1093/cei/uxad016}
}
EUVIMED